Whitehawk Therapeutics unveils ADC pipeline and preclinical data in new corporate presentation
I'm PortAI, I can summarize articles.
Whitehawk Therapeutics Inc. has unveiled its ADC pipeline in a corporate presentation, featuring three assets targeting cancer types like non-small cell lung and ovarian. The presentation highlights novel linker-payload technology for enhanced potency and safety. Preclinical data show improved tumor potency and stability. As of September 2025, Whitehawk has $162.6 million in cash, with a runway into 2028. Key investors include Kalehua and Ally Bridge Group.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments